Skip to main content
. 2013 Feb 25;8(2):e56829. doi: 10.1371/journal.pone.0056829

Figure 6. hPEBP4 knockdown sensitized B-NHL cells to rituximab/CPT-induced apoptosis and growth inhibition.

Figure 6

A. hPEPB4 stably-silenced Raji cells were pretreated with 10 µg/ml rituximab (RTX) or not for 24 hr, and then treated with CPT (1 µM) for 24 hr. Cells were stained with annexin V/PI and analyzed by flow cytometry. B. Cell lysates were subjected to Western blot analysis and probed with anti-procaspase-8, anti-procaspase-3, anti-procaspase-9. C. Silencing of hPEBP4 enhanced the rituximab/CPT-induced growth inhibition when compared with Raji/shNC (P<0.05). Raji/shNC and Raji/shPEBP4 cells were treated with rituximab (10 µg/mL), CPT (1 µM) or rituximab/CPT, and cell proliferation was detected by CCK-8 assay. The values are expressed relative to 0 hr respectively, which are normalized as 1. The values are mean±S.E. of three independent experiments. D. Examination of a panel of cell cycle-related proteins and apoptosis-related proteins after exposure to rituximab or rituximab/CPT.